The deal covers IncellDx's portfolio of immune-oncology & oncology diagnostic products including its single-cell assay for quantifying PD-L1 on tumor cells & immune cell subtypes.
Under the deal, Hong Kong-based Genostics will have the exclusive rights to manufacture and distribute EarlyCDT products in China.
The deal increases US community hospitals' access to BioMérieux's Vidas BRAHMS PCT, the Bact/Alert and Fan Plus Media, and Vitek 2 instrument.
Under the agreement, PGS.Holland will market Bio.logis' Genetic Information Management Suite in Benelux, Scandinavia, and the UK.
Under the non-exclusive agreement, GenDx and its local distributors are authorized to supply several types of QuantStudio systems and service contracts in their respective countries.
Sekisui will distribute Mesa's point-of-care molecular system for flu A/fB in the US and Canada, pending approval from regulators.
The deal covers all Amplidiag tests and the Amplidiag Easyinstrument, and represents Mobidiag's entry into the Baltic region, a company executive said.
Clearbridge subsidiary SAM Laboratory will be the exclusive provider of NanoString's Prosigna breast cancer prognostic gene signature assay in certain countries.
The Singapore-based firm has established a US subsidiary and named distributors to sell its products across Europe, the Middle East, and Asia.
Under the terms of the five-year deal, pharmaceutical company Ferrer will sell SelectMDx test directly to urologists in Spain.